Treatment of dyslipidemia in diabetes

被引：11
作者：
Garber, AJ
Karlsson, FO
机构：
[1] Baylor Coll Med, Dept Med, Houston, TX 77030 USA
[2] Baylor Coll Med, Dept Biochem & Cell Biol, Houston, TX 77030 USA
[3] Baylor Coll Med, Dept Family & Community, Houston, TX 77030 USA
[4] Methodist Hosp, Dept Diabet Endocrinol & Metab, Houston, TX 77030 USA
来源：
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA | 2001年 / 30卷 / 04期
关键词：
D O I：
10.1016/S0889-8529(05)70224-3
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Atherosclerosis kills more patients with diabetes than all other causes combined. Treatment must be focused on several targets: glycemic control, bulk reductions of LDL cholesterol, and shifting LDL particle size. Aggressive treatment and reversal of dyslipidemias is a proven prevention for coronary events in patients with type 2 diabetes. Glycemic control with diet, oral hypoglycemic agents, and insulin, when necessary, often is only partially effective in normalizing lipid values in type 2 diabetes. Intensive treatment with lipid-regulating agents, particularly statins, often is necessary to normalize diabetes-associated dyslipidemias. Statins also are the only agents thus far shown in prospective, controlled trials to reduce the risk of coronary events in diabetic patients definitively.
引用
收藏
页码：999 / +
页数：13
相关论文
共 35 条
[1]   Cardiovascular events and correlates in the Veterans Affairs diabetes feasibility trial - Veterans Affairs Cooperative Study on gylcemic control and complications in type II diabetes [J].
Abraira, C ;
Colwell, J ;
Nuttall, F ;
Sawin, CT ;
Henderson, W ;
Comstock, JP ;
Emanuele, NV ;
Levin, SR ;
Pacold, I ;
Lee, HS ;
Silbert, CK ;
Cxypoliski, R ;
Vasquez, M ;
Kernan, D ;
Niewoehner, C ;
Backes, M ;
Bradley, M ;
Bradley, M ;
Crow, R ;
Rubino, F ;
Bushnell, D ;
Pfeifer, M ;
Service, FJ ;
Howard, B ;
Chew, E ;
Hoogwerf, B ;
Seigel, D ;
Clark, CM ;
Olefsky, JM ;
Porte, D ;
Sussman, KE ;
Johnson, N ;
Christine, B ;
Tir, K ;
Sather, M ;
Day, P ;
Morgan, N ;
Deykin, D ;
Gold, J ;
Huang, P .
ARCHIVES OF INTERNAL MEDICINE, 1997, 157 (02) :181-188
[2]  
*AM DIAB ASS, 2001, DIABETES CARE S1, V24, pS58
[3]  
*AM DIAB ASS, 2001, DIABETES CARE S1, V24, pS44
[4]  
*AM HEART ASS, 1999, 2000 HEART STROK STA
[5]   Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone [J].
Antonucci, T ;
Whitcomb, R ;
McLain, R ;
Lockwood, D .
DIABETES CARE, 1997, 20 (02) :188-193
[6]   Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia [J].
BakkerArkema, RG ;
Davidson, MH ;
Goldstein, RJ ;
Davignon, J ;
Isaacsohn, JL ;
Weiss, SR ;
Keilson, LM ;
Brown, WV ;
Miller, VT ;
Shurzinske, LJ ;
Black, DM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (02) :128-133
[7]  
Best JD, 1996, DIABETES NUTR METAB, V9, P74
[8]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[9]   Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice [J].
Collins, AR ;
Meehan, WP ;
Kintscher, U ;
Jackson, S ;
Wakino, S ;
Noh, G ;
Palinski, W ;
Hsueh, WA ;
Law, RE .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2001, 21 (03) :365-371
[10]   HYPERTRIGLYCERIDEMIA - A CONTRAINDICATION TO THE USE OF BILE-ACID BINDING RESINS [J].
CROUSE, JR .
AMERICAN JOURNAL OF MEDICINE, 1987, 83 (02) :243-248
1234